REG - ReNeuron Group plc - Total Voting Rights

ReNeuronAnnouncement

02/11/2020 07:06

RNS Number : 8509D
  
ReNeuron Group plc
  
02 November 2020
  
 

 
 



2 November 2020


AIM: RENE



 
ReNeuron Group plc
("ReNeuron" or the "Company")
 
Total Voting Rights
 
At 31 October 2020, the Company had 31,876,324 ordinary shares in issue, each carrying one voting right. This follows the issue of 2,000 new shares arising from the exercise of options by staff, such shares having been admitted under the Company's existing block listing arrangement. 
 
As the Company holds no ordinary shares in treasury, the figure of 31,876,324 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.
  
ENDS
 
ENQUIRIES:
 



ReNeuron


+44 (0)20 3819 8400




Olav Hellebø, Chief Executive Officer








Michael Hunt, Chief Financial Officer
 
 








Buchanan (Media/Investor relations)


+44 (0) 20 7466 5000




Mark Court, Tilly Abraham
 
 








Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)


+44 (0) 20 7710 7600




Stewart Wallace, Ben Maddison
(NOMAD and Joint Broker)
 
 








N+1 Singer (Joint Broker)


+44 (0) 20 7496 3000




Aubrey Powell, James Moat, Tom Salvesen







 
 




About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke.  
ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain.  The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
TVRDZMGMLMZGGZM